What data sources are best for building a medical device target account list?

The most valuable data sources include CMS Provider of Services files for facility demographics, CMS Medicare Provider Utilization data for procedure volumes, AHA Annual Survey for organizational details, and CMS Cost Reports for financial health. For commercial data, Definitive Healthcare provides the most comprehensive healthcare facility intelligence. Intent data providers like Bombora and 6sense add behavioral signals showing which accounts are actively researching your device category. State health planning agencies also publish useful facility-level data on procedures and capital expenditures.

How many accounts should be on a medical device ABM target list?

Use a tiered structure: 10 to 25 Tier 1 accounts for fully customized one-to-one campaigns, 50 to 100 Tier 2 accounts for segment-level personalization, and 200 to 500 Tier 3 accounts for programmatic outreach. For a pilot program, start with just 10 to 15 Tier 1 accounts. The total depends on your sales team capacity, marketing budget, and device category. A list of over 1,000 accounts is generally too large for genuine ABM and becomes targeted demand generation instead.

How often should I update my target account list?

Conduct formal quarterly reviews that include score refreshes, win/loss analysis, market change assessment, and sales feedback integration. Between quarterly reviews, update the list immediately when significant events occur, such as facility expansion announcements, competitor recalls, GPO contract renewals, leadership changes, or RFP releases. Expect 20% to 30% of accounts to shift position each quarter. Lists that remain static for more than 90 days are likely missing opportunities.

What criteria should I use to score medical device target accounts?

The most predictive criteria for medical device ABM scoring include procedure volume for your device's clinical application (typically weighted at 25% to 30%), competitive installed base and contract status (15% to 20%), facility financial health (10% to 15%), expansion or renovation plans (10%), existing relationships or champions (10%), intent data signals (10%), and geographic alignment with your sales coverage (5%). Adjust weights based on your specific device category and market dynamics. Validate the scoring model with sales team input.

How do I identify buying committee members at target accounts?

LinkedIn Sales Navigator is the primary tool for identifying stakeholders. Supplement with hospital website leadership pages, physician directories, conference attendee and speaker lists, PubMed research authorship for clinical stakeholders, and your CRM's existing contact database. For each Tier 1 account, map 6 to 10 key stakeholders across clinical, technical, financial, and administrative functions. Document each person's role in the purchasing decision: champion, influencer, decision-maker, or potential blocker.

Should I include ambulatory surgery centers on my target account list?

It depends on your device category. ASCs are the fastest-growing segment of surgical care delivery, with over 6,000 Medicare-certified facilities in the United States. If your device is used in procedures that are migrating from inpatient to outpatient settings, ASCs are essential targets. However, ASCs typically have smaller budgets, simpler buying committees, and shorter sales cycles than hospitals. You may want to handle ASCs through a separate Tier 2 or Tier 3 ABM approach rather than mixing them with hospital targets.

How do GPO affiliations affect target account list building?

GPO affiliations significantly impact your pricing strategy and contract approach. The major GPOs, including Vizient, Premier, HealthTrust, and Intalere, negotiate pricing agreements that their member hospitals can access. Knowing a target account's GPO affiliation helps you understand whether you have an existing contract vehicle, what pricing the account expects, and which GPO relationships you need to develop. GPO contract expiration dates are also valuable timing signals. Accounts whose GPO contracts are approaching renewal are more likely to evaluate alternatives.

What is the difference between a target account list and an ideal customer profile?

The ideal customer profile (ICP) is a template that describes the characteristics of your best-fit customer organization. It includes firmographic criteria like facility type, bed count, and procedure volume, as well as technographic and behavioral criteria. The target account list is the specific set of named organizations that match your ICP and have been scored, prioritized, and organized into tiers. The ICP is the filter; the target account list is the output. You build the ICP first, then apply it to available data to generate your target account list.

What technology stack do I need for medical device ABM target account list management?

A minimum viable ABM stack includes three layers: a healthcare data platform like Definitive Healthcare or ZoomInfo for account enrichment and firmographic data, an intent data provider like Bombora or 6sense for behavioral signals, and a CRM like Salesforce Health Cloud or HubSpot for storing scores, tiers, and engagement history. As your program matures, add an ABM orchestration platform such as Demandbase or 6sense Revenue AI for account-based advertising and multi-channel campaign coordination, and a sales engagement tool like Outreach or SalesLoft for coordinated stakeholder outreach. Ensure any platform you select supports HIPAA-compliant data handling if you are working with protected health information.

How do I build a target account list for a medical device product launch?

For a new product launch, build your TAL in two phases. Phase one uses pre-launch intelligence: identify facilities with the highest procedure volume for your device's clinical indication, map competitive installed bases approaching end-of-life, flag facilities with active clinical trials in your therapeutic area, and layer in intent data showing research activity around the clinical problem your device addresses. Phase two begins at launch: add accounts that engage with your launch content, attend your conference presentations, or respond to early outreach. Expect your initial TAL to shift significantly in the first 6 months as real-world market response data replaces pre-launch assumptions.

How does hospital consolidation affect my target account list strategy?

Hospital consolidation is one of the most important factors in medical device TAL building. Over 60 percent of U.S. community hospitals are now part of a health system, and purchasing decisions are increasingly made at the system level rather than the facility level. Before adding individual hospitals to your list, identify their parent health system and determine where purchasing authority sits. In centralized systems, target the corporate supply chain and value analysis committee. In decentralized systems, individual facility directors may still control capital equipment decisions. Track M and A activity through sources like Kaufman Hall and Becker's Hospital Review to catch system changes before they affect your outreach.

Target Account List Building for Medical Device ABM

Why Your Target Account List Determines ABM Success

In account-based marketing, your target account list is not just a starting point. It is the foundation that every downstream decision rests on. The accounts you choose to pursue determine your content strategy, sales resource allocation, budget distribution, and ultimately your revenue outcomes. Get the list right, and your ABM program has a fighting chance. Get it wrong, and you will spend 12 to 18 months engaging accounts that were never going to buy.

For medical device companies, building a target account list is both more complex and more data-rich than in other B2B sectors. Hospitals and health systems are among the most documented organizations in the country. CMS publishes claims data. State agencies publish facility reports. Professional societies publish membership directories. GPO affiliations are trackable. Procedure volumes are estimable. The information exists. The challenge is synthesizing it into a prioritized list that reflects genuine purchasing potential.

According to Demand Gen Report, 68% of ABM practitioners say account selection is the single most important factor in program success. Yet many medical device companies still build their lists based on gut feel, historical relationships, or simple revenue ranking. These approaches leave significant opportunity on the table. A structured, data-driven approach to target account list building can improve ABM program ROI by 40% or more compared to ad hoc methods.

This guide walks through the complete process of building, validating, and maintaining a target account list for medical device ABM, from defining your ideal customer profile to operationalizing the list within your sales and marketing technology stack.

Defining Your Ideal Customer Profile for Medical Devices

Your ideal customer profile (ICP) is the template against which all potential target accounts are evaluated. For medical device companies, the ICP must capture both firmographic characteristics (what the organization looks like) and behavioral characteristics (how the organization buys).

Firmographic Criteria

Firmographic data describes the structural characteristics of a healthcare organization. For medical device ABM, the most relevant firmographic criteria include:

Facility type: Academic medical center, community hospital, ambulatory surgery center, specialty hospital, critical access hospital, or integrated delivery network. Your device may be best suited for specific facility types based on patient acuity, procedure complexity, or infrastructure requirements.
Bed count and annual admissions: These metrics serve as proxies for facility size and patient volume. A 600-bed academic medical center has different needs, budgets, and decision-making processes than a 50-bed community hospital.
Procedure volume: The most directly relevant metric for most medical devices. If your device is used in total knee replacements, you need to know which facilities perform the highest volume of those procedures. CMS publishes procedure volume data by facility through the Medicare Provider Utilization and Payment Data files.
Geographic location: Territory alignment with your sales team, state regulatory requirements, and regional market dynamics all factor into account prioritization. Some states have Certificate of Need (CON) laws that affect capital equipment purchasing.
GPO affiliation: Group Purchasing Organizations like Vizient, Premier, HealthTrust, and Intalere negotiate contracts on behalf of member hospitals. Knowing which GPO a target account belongs to affects your pricing strategy and contract approach.
Health system affiliation: Many hospitals are part of larger health systems that make purchasing decisions at the corporate level. Identifying these relationships prevents you from targeting individual facilities when the decision is made centrally.
Financial health: Operating margin, days cash on hand, and capital expenditure trends indicate whether a facility has the financial capacity to purchase your device. CMS Cost Reports and bond rating agencies provide this data for nonprofit hospitals.

Technographic Criteria

Technographic data describes the technology environment at a target account. For medical devices, relevant technographic criteria include:

Current installed base: What devices does the account currently use in your category? Are they using a competitor's product, an older generation of your own product, or no device at all? Each scenario requires a different engagement approach.
EHR platform: Epic, Cerner (now Oracle Health), MEDITECH, and other EHR systems have different integration capabilities. If your device connects to the EHR, compatibility matters.
Capital equipment age: Older installations represent replacement opportunities. If a facility's current device is approaching end-of-life or end-of-support, they are likely evaluating alternatives.
Technology adoption pattern: Some facilities are early adopters that embrace new technology aggressively. Others are conservative and wait for extensive clinical evidence and market validation. Match your ABM approach to the account's adoption profile.

Behavioral Criteria

Behavioral data captures how an account interacts with your brand and demonstrates buying intent:

Website engagement: Visits to product pages, pricing pages, or clinical evidence sections from IP addresses associated with target facilities
Content consumption: Downloads of white papers, attendance at webinars, or engagement with clinical evidence materials
Conference attendance: Presence at relevant medical conferences where your company exhibits
Intent signals: Third-party intent data showing research activity related to your device category, competitor products, or relevant clinical topics
Sales interaction history: Previous conversations, demos, evaluations, or RFP responses, even if they did not result in a sale

Data Sources for Medical Device Target Account Lists

The healthcare industry generates an enormous amount of publicly available data that can be used to build and validate target account lists. Here are the most valuable sources:

Government and Regulatory Sources

CMS Provider of Services File: Contains data on every Medicare-certified facility in the United States, including bed count, facility type, services offered, and ownership. Updated quarterly.
CMS Medicare Provider Utilization and Payment Data: Procedure-level claims data by facility and physician. Essential for estimating procedure volumes at target accounts.
CMS Hospital Cost Reports: Financial data for every hospital that participates in Medicare, including revenue, expenses, and capital investment figures.
AHA Annual Survey: The American Hospital Association's comprehensive survey of U.S. hospitals covering staffing, technology, services, and organizational structure. Available through AHA Data Products.
State health planning agencies: Many states publish facility-level data on procedures, outcomes, and capital expenditures through their health planning departments.
FDA MAUDE Database: Medical Device Reporting data that can reveal which devices are in use at specific facilities through adverse event reports. Useful for competitive intelligence.

Commercial Data Providers

Definitive Healthcare: The leading commercial database for healthcare facility intelligence. Provides firmographic, technographic, and physician-level data for hospitals, health systems, ASCs, and physician practices.
IQVIA: Offers medical device market analytics, procedure volume data, and competitive intelligence. Particularly strong in pharmaceutical and device market sizing.
Becker's Hospital Review: Publishes lists and rankings of hospitals by various criteria, useful for identifying high-profile target accounts.
GHX (Global Healthcare Exchange): Supply chain data that can reveal purchasing patterns and vendor relationships at target accounts.

Intent Data Providers

Intent data reveals which accounts are actively researching topics related to your device category. Key providers include:

Bombora: B2B intent data based on content consumption across a cooperative of publisher websites. Can identify accounts showing surge intent for topics related to your device.
6sense: Combines intent data with predictive analytics to score accounts based on their likelihood to purchase.
Demandbase: Provides account identification, intent data, and advertising capabilities in a unified platform.
TechTarget (for health IT): Intent data specifically from healthcare IT publication audiences, valuable for connected medical devices.

For a deeper discussion of how to leverage these data sources in your campaigns, see our guide on medical device marketing strategy.

Free: Medical Device Marketing Guide

Get our comprehensive strategy guide covering surgeon targeting, FDA compliance, SEO, and more.

Download the Guide →

Scoring and Prioritizing Target Accounts

Once you have assembled data on potential target accounts, you need a systematic way to score and prioritize them. A weighted scoring model allows you to rank accounts based on the criteria that matter most to your specific device and market.

Building a Scoring Model

Assign weights to each ICP criterion based on its predictive value for your business. Here is an example scoring model for a surgical device company:

Procedure volume (30% weight): Higher volume facilities represent larger revenue opportunities and faster adoption potential
Competitive installed base (20% weight): Accounts using a specific competitor may be more receptive if that competitor has known limitations
Financial health (15% weight): Facilities with strong financials can make capital purchases without extended budget approval cycles
Facility expansion plans (10% weight): New construction or renovation creates natural purchasing windows
Existing relationship (10% weight): Accounts where you have a champion or previous engagement have higher conversion probability
Intent signals (10% weight): Active research behavior indicates near-term buying interest
Geographic alignment (5% weight): Proximity to sales team coverage for efficient post-sale support

Score each account on a scale of 1 to 10 for each criterion, apply the weights, and calculate a composite score. This creates a ranked list that reflects genuine purchasing potential rather than subjective opinions.

Validation with Sales

No scoring model is perfect. After generating the initial ranked list, validate it with your sales team. They bring qualitative intelligence that data alone cannot capture: relationship dynamics, competitive situations, organizational politics, and timing considerations.

Conduct a structured validation session where sales reviews the top 50 accounts and provides feedback on each. They may flag accounts that should be elevated (strong internal champion, upcoming evaluation cycle) or deprioritized (recent competitor installation with a 5-year contract, organizational dysfunction that prevents purchasing decisions).

This validation step typically results in 20% to 30% of accounts being repositioned on the list. That adjustment is valuable. It represents the synthesis of data-driven analysis and human intelligence that makes a target account list genuinely actionable.

A Worked Scoring Example: From Raw Data to Tier Assignment

Abstract scoring criteria are useful, but a concrete example makes the model actionable. Here is how a surgical robotics company might score three target accounts using the weighted model described above. Each account is scored 1 to 10 on seven criteria, then weighted to produce a composite score out of 10.

Metro Academic Medical Center: Procedure volume 9 (×0.30 = 2.70), competitive installed base 7 (×0.20 = 1.40), financial health 8 (×0.15 = 1.20), expansion plans 6 (×0.10 = 0.60), existing relationship 8 (×0.10 = 0.80), intent signals 7 (×0.10 = 0.70), geographic alignment 9 (×0.05 = 0.45). Composite: 7.85 → Tier 1
Regional Community Hospital: Procedure volume 6 (×0.30 = 1.80), competitive installed base 5 (×0.20 = 1.00), financial health 7 (×0.15 = 1.05), expansion plans 8 (×0.10 = 0.80), existing relationship 4 (×0.10 = 0.40), intent signals 6 (×0.10 = 0.60), geographic alignment 7 (×0.05 = 0.35). Composite: 6.00 → Tier 2
Suburban Ambulatory Surgery Center: Procedure volume 4 (×0.30 = 1.20), competitive installed base 3 (×0.20 = 0.60), financial health 6 (×0.15 = 0.90), expansion plans 2 (×0.10 = 0.20), existing relationship 2 (×0.10 = 0.20), intent signals 8 (×0.10 = 0.80), geographic alignment 8 (×0.05 = 0.40). Composite: 4.30 → Tier 3

Threshold ranges that work for most medical device companies: 7.0 and above for Tier 1, 5.0 to 6.9 for Tier 2, and 3.0 to 4.9 for Tier 3. Accounts scoring below 3.0 fall outside ABM scope and are better served through standard demand generation. Note the ASC example: it scored highest on intent signals (8) but low on other criteria, illustrating why composite scoring prevents the common mistake of chasing intent surges at accounts with poor overall fit.

Build your scoring model in a spreadsheet first, validate the output against sales intuition, then migrate the logic into your CRM or ABM platform for automated scoring. Salesforce Health Cloud and HubSpot both support custom scoring formulas that can be updated as you refine criteria weights over time. For deeper coverage of how AI can automate this scoring process, see our guide on AI-powered ABM for medical devices.

Structuring Your Tiered Account List

With scored and validated accounts, structure your list into tiers that define the level of investment each group receives:

Tier 1: Strategic Accounts (1:1 ABM)

Characteristics: Highest composite scores, largest deal potential, strongest competitive position or internal champion. Typically 10 to 25 accounts.

Investment level: Fully customized campaigns with account-specific content, dedicated account team (sales rep, clinical specialist, marketing support), executive engagement program, custom ROI analyses, and on-site demonstrations. Expected investment of $5,000 to $15,000 per account annually in marketing resources alone.

Tier 2: Growth Accounts (1:Few ABM)

Characteristics: Strong composite scores, meaningful deal potential, shared characteristics that allow segment-level personalization. Typically 50 to 100 accounts grouped into 5 to 8 segments.

Investment level: Semi-customized campaigns at the segment level, industry-specific content and messaging, targeted advertising, coordinated email sequences, and invitation to relevant events. Expected investment of $1,000 to $3,000 per account annually.

Tier 3: Awareness Accounts (1:Many ABM)

Characteristics: Moderate composite scores, represent the addressable market beyond Tier 1 and 2. Typically 200 to 500 accounts.

Investment level: Programmatic advertising, automated email nurture sequences, retargeting, and content syndication. Expected investment under $500 per account annually, primarily through scaled technology-driven tactics.

Mapping the Buying Committee at Target Accounts

A target account list is incomplete without identifying the key stakeholders at each account. For medical device purchases, the buying committee typically includes 6 to 10 individuals across clinical, technical, financial, and administrative functions.

For each Tier 1 account, build a stakeholder map that includes:

Name, title, and role in the purchasing decision (champion, influencer, decision-maker, blocker)
LinkedIn profile and professional background
Published research or conference presentations (for clinical stakeholders)
Known preferences, concerns, or priorities
Current engagement status with your company

LinkedIn Sales Navigator is the primary tool for stakeholder identification. Supplement with physician directories, hospital websites, conference attendee lists, and your CRM's existing contact database. For academic medical centers, PubMed searches can identify physicians who are researching topics relevant to your device.

The goal is not to identify every person at the account. Focus on the 6 to 10 individuals who will directly influence the purchasing decision. Quality of stakeholder intelligence matters far more than quantity of contacts.

Healthcare-Specific Intent Signals That Sharpen Your TAL

Generic B2B intent data tracks web content consumption. Healthcare ABM requires a broader view because medical device buyers leave intent signals across channels that standard intent platforms do not monitor. According to Bombora, 57% to 70% of the B2B buying process occurs before a buyer contacts a vendor, making early intent detection critical for medical device companies with sales cycles averaging 8 to 12 months.

First-Party vs. Third-Party Intent

First-party intent signals come from your own digital properties: product page visits from hospital IP ranges, white paper downloads by buying committee members, webinar registrations, clinical evidence page engagement, and repeat visits to pricing or ROI calculator pages. These signals are high-confidence but low-volume. You will only see them from accounts that already know you exist.

Third-party intent signals come from platforms like Bombora, 6sense, and Demandbase that monitor research activity across thousands of publisher websites. When multiple stakeholders at a target account begin consuming content about topics relevant to your device category, it produces a "surge" signal. A meaningful surge typically unfolds over a 2-week window and involves multiple topic clusters rather than a single keyword.

Healthcare-Specific Intent Sources

Beyond standard B2B intent providers, medical device companies should monitor these healthcare-specific signals:

ClinicalTrials.gov activity: Facilities registering new trials in your therapeutic area are investing in clinical innovation and may be receptive to new device technologies. With over 500,000 registered studies, this database is a rich source of forward-looking intent.
PubMed research authorship: When physicians at a target account publish research related to your device's clinical application, they are building expertise and institutional interest in the space. These individuals often become clinical champions for new technology adoption.
Conference presentation submissions: Clinicians presenting on topics related to your device category at AAOS, ACC, ACS, or specialty conferences are engaged thought leaders who influence purchasing decisions at their institutions.
Capital equipment RFP portals: State and federal procurement databases, GPO bid portals, and hospital RFI announcements signal active purchasing timelines.
Facility construction permits: New OR suites, catheterization labs, or imaging centers create natural device purchasing windows. Monitor state health planning agency filings and Certificate of Need applications.

Combine first-party and third-party signals into a unified intent score at the account level. Accounts showing both types of intent simultaneously should be fast-tracked for Tier 1 consideration. For a comprehensive breakdown of intent data platforms for this use case, read our guide on intent data for medical device marketing.

Maintaining and Evolving Your Target Account List

A target account list is a living document, not a one-time exercise. Healthcare organizations change constantly through mergers, acquisitions, leadership transitions, strategic pivots, and market dynamics. Your list must evolve accordingly.

Quarterly Review Process

Every quarter, review your target account list with the following activities:

Score refresh: Update firmographic and behavioral data for all tiered accounts. Accounts showing increased intent signals may warrant tier promotion. Accounts with declining engagement may need deprioritization or a different approach.
Win/loss analysis: Accounts that converted become case studies and reference accounts. Accounts that were lost should be analyzed for lessons learned and either removed or reclassified with a future re-engagement timeline.
Market changes: Hospital mergers, acquisitions, new facility openings, and leadership changes all affect account priority. Monitor healthcare business publications and CMS data updates for relevant changes.
Sales feedback: Incorporate qualitative feedback from the sales team about account dynamics, competitive situations, and relationship developments.
New account identification: As existing accounts progress through the pipeline, replenish the list with new high-potential accounts to maintain a healthy total.

Signals That Trigger List Updates

Between quarterly reviews, certain events should trigger immediate list updates:

A target account announces a major facility expansion or renovation project
A key competitor receives an FDA warning letter or product recall affecting installations at target accounts
A target account's GPO contract enters its renewal window
Leadership changes at a target account (new CMO, new VP of Supply Chain, new CEO)
A target account publishes an RFP or RFI related to your device category
Significant intent signal surges detected by your intent data platform

Operationalizing Your Target Account List

The best target account list in the world is useless if it lives in a spreadsheet that nobody references. Operationalize your list by integrating it into the systems your teams use daily.

CRM Integration

Load your tiered account list into Salesforce or your CRM of choice. Create custom fields for ABM tier, composite score, key stakeholders, and account engagement status. Set up account-level dashboards that give sales reps visibility into engagement activity across all stakeholders at their assigned accounts. Clean data is essential for this to work; see our guide on CRM data hygiene for medical device companies for best practices.

Marketing Automation

Sync your target account list with your marketing automation platform to enable account-based email campaigns, lead scoring adjustments for target account contacts, and triggered workflows based on account-level engagement milestones.

Advertising Platforms

Upload your target account list to LinkedIn Campaign Manager for account-targeted advertising. Load IP ranges for target facilities into Demandbase or similar platforms for programmatic display advertising. Create custom audiences on social platforms using stakeholder email lists (with appropriate permissions).

Sales Engagement

Configure your sales engagement platform with account-specific sequences and templates. Pre-load stakeholder contact information and personalization tokens so reps can launch coordinated outreach campaigns quickly.

If you are building out your digital presence alongside your ABM program, healthcare SEO services can ensure your target accounts find relevant content when they search for solutions in your device category.

How to Pilot Your Medical Device TAL Program

Launching with a full-scale ABM program across hundreds of accounts is a recipe for diluted effort and unclear results. A structured pilot lets you validate your scoring model, test engagement tactics, and build internal confidence before scaling your investment.

Pilot Parameters

Account count: Start with 10 to 20 accounts that represent a mix of Tier 1 and Tier 2 profiles. Include accounts where you have existing relationships (to test engagement depth) and accounts where you are starting cold (to test awareness-to-engagement conversion).
Timeline: Run the pilot for 90 days minimum. Medical device sales cycles average 8 to 12 months, so a 90-day pilot will not produce closed deals, but it will reveal whether your account selection and engagement approach generate meaningful pipeline activity.
Success criteria: Define measurable thresholds before launch. Reasonable 90-day pilot benchmarks include a target account engagement rate above 40%, at least 3 qualified meetings generated from pilot accounts, and at least 1 opportunity entering the pipeline.
Control group: Maintain a comparable set of non-pilot accounts receiving standard marketing treatment. This allows you to measure the incremental impact of ABM tactics versus business-as-usual demand generation.

Scaling After the Pilot

If the pilot meets or exceeds success criteria, scale methodically. Add 20 to 30 accounts per quarter, maintaining scoring discipline and tier integrity. Resist the pressure to immediately expand to hundreds of accounts. ABM programs that scale too quickly almost always regress to generic demand generation. According to ITSMA, companies with mature ABM programs report 81% higher ROI, but that maturity comes from disciplined execution rather than rapid expansion. For more on orchestrating multi-touch ABM programs across long healthcare sales cycles, see our guide on ABM orchestration for medical devices.

Common Mistakes in Medical Device Target Account List Building

Avoid these frequent pitfalls when building your target account list:

Over-relying on historical revenue data: Your biggest current customers may not be your best future targets. Past revenue does not predict future opportunity, especially if those accounts are already fully penetrated.
Ignoring health system hierarchies: Targeting individual hospitals without understanding their parent health system can lead to duplicated effort and misaligned engagement. Always map facility-to-system relationships.
Building the list in isolation: Marketing builds the list without sales input, or vice versa. Both perspectives are essential. Data provides the foundation; sales intelligence provides the nuance.
Making the list too large: A list of 1,000 "target accounts" is not ABM. It is just a more targeted version of demand generation. Start focused and expand only as you prove results with a smaller list.
Setting and forgetting: The list must be reviewed and updated quarterly at minimum. Healthcare organizations change constantly, and a stale list leads to wasted resources.
Neglecting negative selection criteria: Equally important as knowing who to target is knowing who to exclude. Facilities that are financially distressed, recently acquired (and in integration limbo), or under regulatory sanctions may not be viable targets regardless of their procedure volume.

Measuring Target Account List Effectiveness

Track these metrics to evaluate whether your target account list is well-constructed:

Engagement rate by tier: Tier 1 accounts should show the highest engagement rates. If Tier 3 accounts are engaging more than Tier 1, your prioritization criteria may be misaligned.
Pipeline conversion rate: What percentage of target accounts enter your pipeline? Industry benchmarks for medical device ABM suggest 20% to 30% of Tier 1 accounts should enter the pipeline within 12 months.
Average deal size by tier: Tier 1 deals should be significantly larger than lower tiers, validating your prioritization of those accounts.
Sales acceptance rate: What percentage of marketing-identified accounts does sales actively pursue? Low acceptance rates indicate misalignment between marketing's selection criteria and sales' on-the-ground reality.
List stability: How much does the list change each quarter? Some change is healthy (20% to 30%), but excessive churn suggests your ICP criteria are not stable or your data sources are unreliable.

Your target account list is a strategic asset that deserves ongoing investment and refinement. The medical device companies that build, validate, and maintain their lists with discipline consistently outperform those that treat account selection as an afterthought. For a complete framework on medical device marketing strategy, explore how ABM fits into a broader go-to-market approach.